Phase 3 Clinical Trials With Primary Completion Dates in March 2025
This is a list of Phase 3 trials with primary completion dates in March 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | 2025-03-01 | Phase 3 | NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer |
| IMVT | Immunovant, Inc. | 2025-03-01 | Phase 3 | NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
| IONS | Ionis Pharmaceuticals, Inc. | 2025-03-01 | Phase 3 | NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia |
| NICXF | Nicox S.A. | 2025-03-01 | Phase 3 | NCT04630808 | MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension |
| NMRA | Neumora Therapeutics, Inc. | 2025-03-01 | Phase 3 | NCT06058039 | Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder |
| OTLK | Outlook Therapeutics, Inc. | 2025-03-01 | Phase 3 | NCT05112861 | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders |
| RARE | Ultragenyx Pharmaceutical Inc. | 2025-03-01 | Phase 3 | NCT05345171 | Clinical Study of DTX301 AAV- Mediated Gene Transfer for Ornithine Transcarbamylase(OTC) Deficiency |